Inside the biology of early T-cell precursor acute lymphoblastic leukemia: the perfect trick.

ETP-ALL biology Lymphoid-myeloid potential Molecular pathogenesis.

Journal

Biomarker research
ISSN: 2050-7771
Titre abrégé: Biomark Res
Pays: England
ID NLM: 101607860

Informations de publication

Date de publication:
20 Dec 2021
Historique:
received: 29 09 2021
accepted: 23 11 2021
entrez: 21 12 2021
pubmed: 22 12 2021
medline: 22 12 2021
Statut: epublish

Résumé

Early T-cell precursor acute lymphoblastic leukemia (ETP-ALL) is a rare, distinct subtype of T-ALL characterized by genomic instability, a dismal prognosis and refractoriness to standard chemotherapy. Since its first description in 2009, the expanding knowledge of its intricate biology has led to the definition of a stem cell leukemia with a combined lymphoid-myeloid potential: the perfect trick. Several studies in the last decade aimed to better characterize this new disease, but it was recognized as a distinct entity only in 2016. We review current insights into the biology of ETP-ALL and discuss the pathogenesis, genomic features and their impact on the clinical course in the precision medicine era today.

Identifiants

pubmed: 34930475
doi: 10.1186/s40364-021-00347-z
pii: 10.1186/s40364-021-00347-z
pmc: PMC8686563
doi:

Types de publication

Journal Article Review

Langues

eng

Pagination

89

Informations de copyright

© 2021. The Author(s).

Références

Eur J Haematol. 2014 Mar;92(3):211-8
pubmed: 24329989
Blood. 2013 Sep 19;122(12):2093-103
pubmed: 23926305
Br J Haematol. 2014 Aug;166(3):421-4
pubmed: 24708207
J Biomed Sci. 2020 Jul 21;27(1):81
pubmed: 32690020
PLoS One. 2013;8(1):e53190
pubmed: 23359050
Nature. 2008 Apr 10;452(7188):768-72
pubmed: 18401412
J Exp Med. 2011 Dec 19;208(13):2571-9
pubmed: 22162831
Br J Haematol. 2019 Aug;186(4):538-548
pubmed: 31115909
Immunity. 2007 Jun;26(6):678-89
pubmed: 17582341
Nature. 2012 Jan 11;481(7380):157-63
pubmed: 22237106
Blood. 2015 Mar 12;125(11):1759-67
pubmed: 25645356
Cancer Cell. 2018 Feb 12;33(2):274-291.e8
pubmed: 29438697
Onco Targets Ther. 2021 Jun 18;14:3795-3802
pubmed: 34168464
Am J Hematol. 2021 May 1;96(5):589-598
pubmed: 33639000
Blood. 2013 Jun 6;121(23):4749-52
pubmed: 23603912
Haematologica. 2014 Jan;99(1):94-102
pubmed: 23975177
Nature. 2008 Apr 10;452(7188):764-7
pubmed: 18401411
Leuk Res. 2013 Sep;37(9):1027-34
pubmed: 23827350
Leukemia. 2020 Aug;34(8):2198-2205
pubmed: 32457355
J Exp Med. 2014 Apr 7;211(4):701-13
pubmed: 24687960
J Immunol. 2010 Jul 1;185(1):284-93
pubmed: 20543111
Blood Cancer J. 2012 Jan;2(1):e55
pubmed: 22829239
J Exp Med. 2005 Jul 4;202(1):21-31
pubmed: 15983065
J Hematol Oncol. 2016 Sep 22;9(1):95
pubmed: 27658391
Cell Rep. 2016 Mar 1;14(8):1953-65
pubmed: 26904942
Nat Genet. 2017 Aug;49(8):1211-1218
pubmed: 28671688
Ther Adv Hematol. 2020 Jul 16;11:2040620720929475
pubmed: 32733662
Lancet Oncol. 2009 Feb;10(2):147-56
pubmed: 19147408
Blood. 2005 Mar 1;105(5):1930-6
pubmed: 15522952
J Clin Invest. 2021 Jun 24;:
pubmed: 34166225
Br J Haematol. 2012 Feb;156(3):358-65
pubmed: 22128890
Nat Genet. 2020 Apr;52(4):388-400
pubmed: 32203470
Blood. 2021 Sep 2;138(9):773-784
pubmed: 33876209
Leuk Res. 2019 Mar;78:3-11
pubmed: 30641417
Cancer Cell. 2002 Feb;1(1):75-87
pubmed: 12086890
Immunity. 2004 Jun;20(6):735-45
pubmed: 15189738
Blood. 2005 Jul 1;106(1):274-86
pubmed: 15774621
Blood. 2014 Dec 11;124(25):3738-47
pubmed: 25301704
Nat Commun. 2015 Jan 07;6:5794
pubmed: 25565005
Blood. 2016 May 19;127(20):2391-405
pubmed: 27069254
Int J Mol Sci. 2021 Apr 26;22(9):
pubmed: 33925883
Blood. 2017 Jan 26;129(4):424-447
pubmed: 27895058
Blood. 2016 Apr 14;127(15):1863-9
pubmed: 26747249
Cancer Discov. 2014 Sep;4(9):1074-87
pubmed: 24994123
Medicine (Baltimore). 2018 Oct;97(41):e12743
pubmed: 30313079
Cold Spring Harb Mol Case Stud. 2015 Oct;1(1):a000539
pubmed: 27148573
Nat Immunol. 2012 Feb 19;13(4):412-9
pubmed: 22344248
Cancer Cell. 2011 Apr 12;19(4):484-97
pubmed: 21481790
Blood. 2011 Oct 27;118(17):4646-56
pubmed: 21828136
Int J Lab Hematol. 2019 Apr;41(2):e32-e37
pubmed: 30407727
Nat Commun. 2021 Jun 17;12(1):3708
pubmed: 34140506

Auteurs

Francesco Tarantini (F)

Department of Emergency and Organ Transplantation (D.E.T.O.) - Hematology and Stem Cell Transplantation Unit, University of Bari "Aldo Moro", P.zza G. Cesare, 11, 70124, Bari, Italy.

Cosimo Cumbo (C)

Department of Emergency and Organ Transplantation (D.E.T.O.) - Hematology and Stem Cell Transplantation Unit, University of Bari "Aldo Moro", P.zza G. Cesare, 11, 70124, Bari, Italy.

Luisa Anelli (L)

Department of Emergency and Organ Transplantation (D.E.T.O.) - Hematology and Stem Cell Transplantation Unit, University of Bari "Aldo Moro", P.zza G. Cesare, 11, 70124, Bari, Italy.

Antonella Zagaria (A)

Department of Emergency and Organ Transplantation (D.E.T.O.) - Hematology and Stem Cell Transplantation Unit, University of Bari "Aldo Moro", P.zza G. Cesare, 11, 70124, Bari, Italy.

Giorgina Specchia (G)

School of Medicine, University of Bari "Aldo Moro", 70124, Bari, Italy.

Pellegrino Musto (P)

Department of Emergency and Organ Transplantation (D.E.T.O.) - Hematology and Stem Cell Transplantation Unit, University of Bari "Aldo Moro", P.zza G. Cesare, 11, 70124, Bari, Italy.

Francesco Albano (F)

Department of Emergency and Organ Transplantation (D.E.T.O.) - Hematology and Stem Cell Transplantation Unit, University of Bari "Aldo Moro", P.zza G. Cesare, 11, 70124, Bari, Italy. francesco.albano@uniba.it.

Classifications MeSH